A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta

Drugs and Aging

Volumn 21, Issue 3, 2004, Pages 187-201

  Nicholas, Johann C B ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1S; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; SUCROSE;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD VESSEL FISTULA; CATHETER; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; TIME SERIES ANALYSIS; VASCULAR ACCESS;

AGED; AGED, 80 AND OVER; AGING; ANEMIA; COMORBIDITY; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FERRITINS; GERIATRICS; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542614367     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421030-00004     Document Type: Article

References (46)

1. Ansell D, Feest T. The fifth annual report: the UK renal registry, 2002. Renal Registry, editor. Bristol: Renal Registry, 2002
2. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases. USRDS 2002 annual data report [online]. Available from URL: http://www.usrds.org [Accessed 2004 Feb 2]
3. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). 25th Report of the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Woodville (SA): ANZDATA; 2002 Jan 1
4. Moreno F, Aracil FJ, Perez R, et al. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kid Dis 1996; 27 (4): 548-56
5. Royal College of Physicians of London and the Renal Association, Standards Subcommittee of the Renal Association. Treatment of adult patients with renal failure: recommended standards and audit measures. 2nd ed. London: Royal College of Physicians of London and the Renal Association, 1997
6. Khan IH, Catto GR, Edward N, et al. Influence of coexisting disease on survival on renal-replacement therapy. Lancet 1993; 341 (8842): 415-8
7. Jacobs C, Horl WH, Macdougall IC, et al. European best practice guidelines 5: target haemoglobin. Nephrol Dial Transplant 2000; 15 Suppl. 4: 15-9
8. Kalantar-Zadeh K, Don B, Rodriguez R, et al. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001; 37 (3): 564-72
9. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58 (3): 1325-35
10. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20 (4): 345-9
11. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [abstract]. N Engl J Med 1998; 339 (9): 584
12. Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in predialysis and dialysis patients. Nephrol Dial Transplant 2003; 18 (2): 353-61
13. Jungers P, Massy ZA, Nguyen-Khoa T, et al. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 2001; 16 (12): 2357-64
14. Roderick P, Jones C, Drey N, et al. Late referral for end-stage renal disease: a region-wide survey in the south west of England. Nephrol Dial Transplant 2002; 17 (7): 1252-9
15. Levin A. Consequences of late referral on patient outcomes. Nephrol Dial Transplant 2000; 15 (90003): 8-13
16. Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis 2001; 38 (3): 494-501
17. Combe C, Pisoni RL, Port FK, et al. Dialysis outcomes and practice patterns study: data on the use of central venous catheters in chronic hemodialysis. Nephrologie 2001; 22 (8): 379-84
18. Xue J, St Peter W, Ebben J, et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002; 40 (6): 1153-61
19. Jungers PY, Robino C, Choukroun G, et al. Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant 2002; 17 (9): 1621-7
20. Macdougall IC. CREATE: new strategies for early anaemia management in renal insufficiency. CREATE Study Group. Nephrol Dial Transplant 2003; 18 Suppl. 2: 13-6
21. McMahon LP, Mason K, Skinner SL, et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15 (9): 1425-30
22. Weiss LG, Clyne N, Divino FJ, et al. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multi-centre trial: Swedish Study Group. Nephrol Dial Transplant 2000; 15 (12): 2014-9
23. Locatelli F, Baldamus CA, Villa G, et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002; 40 (1): 119-25
24. Jones CH, Richardson D. Which EPO dose per week [letter]? Nephrol Dial Transplant 2002; 17 (10): 1855
25. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 Suppl. 3: 14-21
26. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60 (2): 741-7
27. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346 (7): 469-75
28. Horl WH, Cavill I, Macdougall IC, et al. How to diagnose and correct iron deficiency during r-huEPO therapy: a consensus report. Nephrol Dial Transplant 1996; 11 (2): 246-50
29. Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10 (5): 607-14
30. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50 (5): 1694-9
31. Taylor JE, Peat N, Porter C, et al. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996; 11 (6): 1079-83
32. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13 (6): 381-4
33. Macdougall IC, Chandler G, Elston O, et al. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999; 34 (4 Suppl. 2): S40-6
34. Kletzmayr J, Horl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002; 17 Suppl. 2: 25-9
35. Parkkinen J, von Bonsdorff L, Peltonen S, et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000; 15 (11): 1827-34
36. Patruta SI, Edlinger R, Sunder-Plassmann G, et al. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9 (4): 655-63
37. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intimamedia thickness in end-stage renal disease. Circulation 2002; 106 (17): 2212-7
38. Kaltwasser JP, Werner E, Becker H. Serum ferritin as a control parameter for oral iron therapy. Dtsch Med Wochenschr 1977; 102 (32): 1150-5
39. Kaltwasser JP, Gottschalk R. Erythropoietin and iron. Kidney Int 1999; 69 Suppl.: 49-56
40. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000 [online]. Available from URL: http://www.kidney.org/ professionals/Kdoqi/index.cfm [Accessed 2004 Feb 13]
41. Macdougall IC. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy: merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant 1998; 13 (4): 847-9
42. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16 (7): 1416-23
43. Brugnara C. A hematologic "gold standard" for iron-deficient states? Clin Chem 2002; 48 (7): 981-2
44. Jones CH, Richardson D, Ayers S, et al. Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. Nephrol Dial Transplant 1998; 13 (11): 2873-6
45. Mast AE, Blinder MA, Lu Q, et al. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002; 99 (4): 1489-91
46. Fishbane S, Galgano C, Langley Jr RC, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997; 52 (1): 217-22